Instrument Inactif

Communiqués Stem Cell Therapeutics Corp. Xetra

Actions

R5W

CA8585721001

Cours en clôture Xetra
- ^EUR	-

12/01/22	TCR2 Therapeutics nomme un directeur des affaires et de la stratégie	MT
13/12/21	Pfizer veut renforcer son expertise dans le domaine des maladies immuno-inflammatoires en rachetant Arena Pharmaceuticals pour 6,7 milliards de dollars.	MT

Communiqués

17/11/21	Trillium Therapeutics : Pfizer Completes Acquisition of Trillium Therapeutics - Form 8-K	PU
17/11/21	TRILLIUM THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/11/21	TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)	AQ
12/11/21	Trillium: Q3 Earnings Snapshot	AQ
12/11/21	TRILLIUM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
29/10/21	Trillium Therapeutics Receives Final Court Order Approving Arrangement - Form 8-K	PU
29/10/21	TRILLIUM THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
28/10/21	Trillium Therapeutics Receives Final Court Order Approving Arrangement	GL
27/10/21	Trillium Securityholders Approve Acquisition by Pfizer - Form 8-K	PU
27/10/21	TRILLIUM THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/10/21	Trillium Therapeutics : Material Event - Form 8-K	PU
20/10/21	TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)	AQ
15/10/21	TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)	AQ
13/10/21	TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)	AQ
24/08/21	TRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium Therapeutics Inc. - TRIL	BU
23/08/21	Trillium Therapeutics : Pfizer signs deal to buy Trillium Therapeutics for US$2.26 billion	AQ
23/08/21	Trillium Therapeutics : VOTING SUPPORT AGREEMENT (Form 8-K)	PU
23/08/21	TRILLIUM THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
16/08/21	Trillium Therapeutics : Reports Second Quarter 2021 Operating and Financial Results	AQ
13/08/21	Trillium: Q2 Earnings Snapshot	AQ
13/08/21	TRILLIUM THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
13/08/21	Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results	GL
09/08/21	Trillium Therapeutics : Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia	AQ
06/07/21	Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia	GL
30/06/21	TRILLIUM THERAPEUTICS : APPOINTS CATHERINE MACKEY, PH.D., TO ITS BOARD OF DIRECTORS (Form 8-K)	PU